Home   >  
Angiogenesis/Protein Tyrosine Kinase
  >  
ALK

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products

Antibodies

Peptides

Catalysts

Impurities

Intermediate

Raw Materials

ALK

Chemical Structure Cat. No. Product Name CAS No.
SM16 Chemical Structure
 BCP30149 SM16 614749-78-9
SM16 is a ALK5/ALK4 kinase inhibitor with Kis of 10 and 1.5 nM, respectively.
BIO-013077-01 Chemical Structure
 BCP30129 BIO-013077-01 746667-48-1
BIO-013077-01 is a novel potent antagonist of the TGFbeta family type I receptors, Alk5 and/or Alk4.
GW-6604 Chemical Structure
 BCP13570 GW-6604 452342-37-9
GW6604 is a potent and selective ALK-5 inhibitor with potent anticancer activity.
Belizatinib Chemical Structure
 BCP29521 Belizatinib 1357920-84-3
Belizatinib is an oral, dual, potent inhibitor of ALK and TRKA, TRKB, and TRKC, with IC50 of 0.7 nM for wild-type recombinant ALK kinase.
Ensartinib dihydrochloride Chemical Structure
 BCP29059 Ensartinib dihydrochloride 2137030-98-7
Ensartinib, also known as X-396, is a potent and dual ALK/MET inhibitor with IC50s of <0.4 nM and 0.74 nM, respectively.
LDN-193189 2HCl Chemical Structure
 BCP20431 LDN-193189 2HCl 1435934-00-1
LDN193189 is a highly potent small molecule BMP inhibitor with IC50 of 5 and 30 nM for ALK2 and ALK3, respectively.
Alectinib Hydrochloride Chemical Structure
 BCP09075 Alectinib Hydrochloride 1256589-74-8
CH5424802 Hydrochloride is a potent, selective, and orally available ALK inhibitor with IC50 of 1.9 nM, the dissociation constant (KD) value for ALK in an ATP-competitive manner is 2.4 nM using a competition-bind assay.
ALK inhibitor 1 Chemical Structure
 BCP28167 ALK inhibitor 1 761436-81-1
ALK inhibitor 1 is a novel and selective inhibitor for the ALK kinase.
HG-14-10-04 Chemical Structure
 BCP24835 HG-14-10-04 1356962-34-9
HG-14-10-04 is a potent and specific ALK inhibitor with IC50 of 20 nM.
CEP-28122 Chemical Structure
 BCP15177 CEP-28122 1022958-60-6
CEP-28122 is a highly potent and selective orally active ALK inhibitor with a favorable pharmaceutical and pharmacokinetic profile and robust and selective pharmacologic efficacy against ALK-positive human cancer cells and tumor xenograft models in mice.
123下一页共 29 条记录 1 / 3 页 
0086-13720134139